Blue Jet Healthcare Limited (BLUEJET) AI Stock Analysis

• Market Cap: ₹56.77B
• Dividend Yield: 0.22%
• Average Volume (3M): 19.19K
• Price to Earnings (P/E): 57.2
• Beta (1Y): 1.03
• Revenue Growth: 63.34%
• EPS Growth: 109.89%
• Country: IN
• Employees: 447
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 2.30
• Shares Outstanding: 173,465,420
• 10 Day Avg. Volume: 15,409
• 30 Day Avg. Volume: 19,187
• PEG Ratio: 0.55
• Price to Book (P/B): 12.87
• Price to Sales (P/S): 14.16
• P/FCF Ratio: -427.53
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 25.37
• Revenue Forecast (FY): ₹16.51B

• Rating: 65 Neutral
• Price Target: ₹369.00 ▼(-43.53% Downside)
• Action: Reiterated Date: 02/14/26
• Date: Action: Reiterated 02/14/26

The score is driven primarily by strong financial performance (growth, margins, and a low-debt balance sheet), tempered by weak free cash flow generation. Technical indicators are the main near-term risk due to a pronounced downtrend despite oversold conditions, while valuation appears moderate with a low dividend yield.

Positive Factors

Robust revenue growth and expanding margins

Sustained 45% revenue growth and materially higher gross and net margins reflect durable demand for Blue Jet's products and effective cost control. This strengthening of top-line scale and margin structure improves long-term earnings power and reinvestment capacity, supporting growth over the next 2–6 months and beyond.

Negative Factors

Negative free cash flow in 2025

A swing to negative free cash flow signals cash strain despite accounting profits. Persistent negative FCF can constrain reinvestment, debt reduction, or shareholder returns, forcing external funding or capex cuts. This undermines financial optionality and heightens execution risk over the coming months.

Blue Jet Healthcare Limited Business Overview & Revenue Model

Company Description

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for applications in pharmaceutical and healthcare products. It provides integrated contrast media interm...

Read more

Blue Jet Healthcare Limited engages in the manufacturing and sale of pharmaceutical intermediates and active pharmaceutical ingredients (APIs) for applications in pharmaceutical and healthcare products. It provides integrated contrast media interm...

How the Company Makes Money

BLUEJET primarily makes money by selling APIs and API intermediates to pharmaceutical companies, which use these inputs to manufacture finished medicines. Revenue is generated on a business-to-business basis through (a) direct sales of its manufac...

Read more

BLUEJET primarily makes money by selling APIs and API intermediates to pharmaceutical companies, which use these inputs to manufacture finished medicines. Revenue is generated on a business-to-business basis through (a) direct sales of its manufac...

Blue Jet Healthcare Limited Financial Statement Overview

Breakdown	TTM	Mar 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Income Statement
Total Revenue	11.79B	10.30B	7.10B	7.18B	6.77B	4.94B
Gross Profit	6.16B	5.69B	3.89B	2.70B	2.97B	2.47B
EBITDA	4.85B	4.24B	2.48B	2.43B	2.69B	2.15B
Net Income	3.52B	3.05B	1.64B	1.60B	1.82B	1.38B
Balance Sheet
Total Assets	15.27B	14.18B	10.59B	8.62B	7.13B	5.36B
Cash, Cash Equivalents and Short-Term Investments	4.11B	3.06B	3.09B	2.55B	1.81B	979.70M
Total Debt	206.29M	199.86M	16.13M	68.31M	228.39M	516.15M
Total Liabilities	2.72B	2.84B	2.14B	1.81B	1.92B	1.96B
Stockholders Equity	12.56B	11.33B	8.45B	6.81B	5.22B	3.40B
Cash Flow
Free Cash Flow	817.22M	-341.15M	669.59M	822.79M	1.21B	807.67M
Operating Cash Flow	2.07B	457.65M	2.41B	1.42B	1.46B	1.30B
Investing Cash Flow	-1.65B	-351.83M	-2.64B	-1.47B	-760.26M	-566.48M
Financing Cash Flow	-85.36M	-185.57M	-19.86M	-42.33M	-561.45M	-221.90M

Blue Jet Healthcare Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 653.45
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLUEJET, the sentiment is Negative. The current price of 653.45 is above the 20-day moving average (MA) of 366.64, above the 50-day MA of 397.46, and above the 200-day MA of 623.87, indicating a bearish trend. The MACD of -17.46 indicates Positive momentum. The RSI at 34.32 is Neutral, neither overbought nor oversold. The STOCH value of 16.19 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:BLUEJET.

Blue Jet Healthcare Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	68 Neutral	₹45.48B	30.45	―	0.13%	14.35%	15.79%
CONCORDBIO	66 Neutral	₹106.28B	54.58	―	0.80%	3.63%	-1.21%
BLUEJET	65 Neutral	₹56.77B	57.24	―	0.22%	63.34%	109.89%
BIOCON	63 Neutral	₹584.34B	91.56	―	0.12%	10.62%	-66.88%
JUBLINGREA	61 Neutral	₹86.59B	59.25	―	0.74%	3.80%	64.94%
SYNGENE	61 Neutral	₹157.25B	439.86	―	0.19%	8.57%	-2.93%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Blue Jet Healthcare Limited Corporate Events